ISOXAZOLINE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME

摘要

The present application describes novel isoxazoline of formula I or II: [TWO CHEMICAL STRUCTURES]or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, R1, R2, R3, R4, Z, U, X, Y, Za, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-a converting enzyme (TACE), or a combination thereof.